DrugPatentWatch Database Preview
Drugs in Development Information for IMC-1C11
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug IMC-1C11?
IMC-1C11 is an investigational drug.
There have been 80 clinical trials for IMC-1C11.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2015.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Eli Lilly and Company, National Cancer Institute (NCI), and ImClone LLC.
There are eighteen US patents protecting this investigational drug and one hundred and seventy-five international patents.
Summary for IMC-1C11
| US Patents | 18 |
| International Patents | 175 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2015-09-01) |
| Vendors | 0 |
Recent Clinical Trials for IMC-1C11
| Title | Sponsor | Phase |
|---|---|---|
| Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage | University Hospital Inselspital, Berne | N/A |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Immunocore Ltd | Phase 1/Phase 2 |
| Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers | Asan Medical Center | Phase 2 |
Clinical Trial Summary for IMC-1C11
Top disease conditions for IMC-1C11
Top clinical trial sponsors for IMC-1C11
US Patents for IMC-1C11
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| IMC-1C11 | Start Trial | Method and compositions for treating cancerous tumors | Start Trial | |
| IMC-1C11 | Start Trial | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (Marseilles, FR) | Start Trial |
| IMC-1C11 | Start Trial | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, PA) | Start Trial |
| IMC-1C11 | Start Trial | Methods of inducing responsiveness to anti-angiogenic agent | Vascular Biogenics Ltd. (Modi'in, IL) | Start Trial |
| IMC-1C11 | Start Trial | Induction of tumor hypoxia for cancer therapy | VIRGINIA COMMONWEALTH UNIVERSITY (Richmond, VA) | Start Trial |
| IMC-1C11 | Start Trial | Method and compositions for treating cancerous tumors | Start Trial | |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for IMC-1C11
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| IMC-1C11 | Australia | 2014233757 | 2033-03-18 | Start Trial |
| IMC-1C11 | Brazil | 112015023948 | 2033-03-18 | Start Trial |
| IMC-1C11 | Canada | 2902734 | 2033-03-18 | Start Trial |
| IMC-1C11 | China | 105102442 | 2033-03-18 | Start Trial |
| IMC-1C11 | European Patent Office | 2976333 | 2033-03-18 | Start Trial |
| IMC-1C11 | Japan | 2016519091 | 2033-03-18 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
